Despite the success of antiretroviral therapy (ART) for people living with HIV, lifelong
treatment is required and there is no cure. HIV can integrate in the host genome and persist …

Although antiretroviral therapy (ART) can reduce viremia to below the limit of detection and
allow persons living with HIV-1 (PLWH) to lead relatively normal lives, viremia rebounds …

HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is
effective but requires lifelong drug administration owing to a stable reservoir of latent …

In people living with HIV (PLWH) on antiretroviral therapy (ART), virus persists in a latent
form where there is minimal transcription or protein expression. Latently infected cells are a …

Abstract HIVACAT T-cell immunogen (HTI) is a novel human immunodeficiency virus (HIV)
vaccine immunogen designed to elicit cellular immune responses to HIV targets associated …

Antiretroviral therapy (ART) effectively inhibits HIV-1 replication but is not curative due to the
persistence of a latent viral reservoir in resting CD4+ T cells. This reservoir is a major barrier …

BACKGROUND Chimeric antigen receptor (CAR) T cells have emerged as an approach to
treat malignant tumors. This strategy has also been proposed for the treatment of HIV-1 …

Understanding the complexity of the long-lived HIV reservoir during antiretroviral therapy
(ART) remains a considerable impediment in research towards a cure for HIV. To address …

Quantifying the replication-competent HIV reservoir is essential for evaluating curative
strategies. Viral outgrowth assays (VOAs) underestimate the reservoir because they fail to …

The major barrier to cure HIV infection is the early generation and extended survival of HIV
reservoirs in the circulation and tissues. Currently, the techniques used to detect and …